Lonza said it will focus on its core business including drug development, with restructuring and a divestment planned to boost growth. As part of the review, the Swiss life-science company said it ...

July 23 (Reuters) - Switzerland's Lonza (LONN.S), opens new tab posted 23% growth in its half-year core profit on Wednesday, beating market expectations, driven by a strong performance in its contract ...

Sustainable high market growth ahead with supportive margin recovery. There are limited tariff risks. Lonza is a potential beneficiary given the ample availability of the USA industrial capacities ...

Lonza Group AG reported robust financial performance for the full year 2025, with revenue and earnings showing significant growth. Despite these positive results, the company’s stock fell by 3.39% ...

Despite a challenging economic environment, Lonza announced an increase in CAPEX, positioning itself to capture long-term growth opportunities in the healthcare sector. We positively favor Lonza's ...